Effectiveness and safety of COVID-19 vaccination in people with blood cancer
<p><strong>Background:</strong> People with blood cancer have increased risk of severe COVID-19 outcomes and poor response to vaccination. We assessed the safety and effectiveness of COVID-19 vaccines in this vulnerable group compared to the general population.</p> <br>...
| Үндсэн зохиолчид: | , , , , , , |
|---|---|
| Формат: | Journal article |
| Хэл сонгох: | English |
| Хэвлэсэн: |
Elsevier
2024
|
| _version_ | 1826317310124621824 |
|---|---|
| author | Copland, E Hirst, J Mi, E Patone, M Chen, D Coupland, C Hippisley-Cox, J |
| author_facet | Copland, E Hirst, J Mi, E Patone, M Chen, D Coupland, C Hippisley-Cox, J |
| author_sort | Copland, E |
| collection | OXFORD |
| description | <p><strong>Background:</strong> People with blood cancer have increased risk of severe COVID-19 outcomes and poor response to vaccination. We assessed the safety and effectiveness of COVID-19 vaccines in this vulnerable group compared to the general population.</p>
<br>
<p><strong>Methods:</strong> Individuals aged ≥12 years as of 1st December 2020 in the QResearch primary care database were included. We assessed adjusted COVID-19 vaccine effectiveness (aVE) against COVID-19-related hospitalisation and death in people with blood cancer using a nested matched case-control study. Using the self-controlled case series methodology, we compared the risk of 56 pre-specified adverse events within 1–28 days of a first, second or third COVID-19 vaccine dose in people with and without blood cancer.</p>
<br>
<p><strong>Findings:</strong> The cohort comprised 12,274,948 individuals, of whom 81,793 had blood cancer. COVID-19 vaccines were protective against COVID-19-related hospitalisation and death in people with blood cancer, although they were less effective, particularly against COVID-19-related hospitalisation, compared to the general population. In the blood cancer population, aVE against COVID-19-related hospitalisation was 64% (95% confidence interval [CI] 48%−75%) 14–41 days after a third dose, compared to 80% (95% CI 78%−81%) in the general population. Against COVID-19-related mortality, aVE was >80% in people with blood cancer 14–41 days after a second or third dose. We found no significant difference in risk of adverse events 1–28 days after any vaccine dose between people with and without blood cancer.</p>
<br>
<p><strong>Interpretation:</strong> Our study provides robust evidence which supports the use of COVID-19 vaccinations for people with blood cancer.</p> |
| first_indexed | 2025-02-19T04:36:27Z |
| format | Journal article |
| id | oxford-uuid:7f3f8b33-41bb-454f-9222-a967a221b6ac |
| institution | University of Oxford |
| language | English |
| last_indexed | 2025-02-19T04:36:27Z |
| publishDate | 2024 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:7f3f8b33-41bb-454f-9222-a967a221b6ac2025-01-31T16:41:04ZEffectiveness and safety of COVID-19 vaccination in people with blood cancerJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7f3f8b33-41bb-454f-9222-a967a221b6acEnglishSymplectic ElementsElsevier2024Copland, EHirst, JMi, EPatone, MChen, DCoupland, CHippisley-Cox, J<p><strong>Background:</strong> People with blood cancer have increased risk of severe COVID-19 outcomes and poor response to vaccination. We assessed the safety and effectiveness of COVID-19 vaccines in this vulnerable group compared to the general population.</p> <br> <p><strong>Methods:</strong> Individuals aged ≥12 years as of 1st December 2020 in the QResearch primary care database were included. We assessed adjusted COVID-19 vaccine effectiveness (aVE) against COVID-19-related hospitalisation and death in people with blood cancer using a nested matched case-control study. Using the self-controlled case series methodology, we compared the risk of 56 pre-specified adverse events within 1–28 days of a first, second or third COVID-19 vaccine dose in people with and without blood cancer.</p> <br> <p><strong>Findings:</strong> The cohort comprised 12,274,948 individuals, of whom 81,793 had blood cancer. COVID-19 vaccines were protective against COVID-19-related hospitalisation and death in people with blood cancer, although they were less effective, particularly against COVID-19-related hospitalisation, compared to the general population. In the blood cancer population, aVE against COVID-19-related hospitalisation was 64% (95% confidence interval [CI] 48%−75%) 14–41 days after a third dose, compared to 80% (95% CI 78%−81%) in the general population. Against COVID-19-related mortality, aVE was >80% in people with blood cancer 14–41 days after a second or third dose. We found no significant difference in risk of adverse events 1–28 days after any vaccine dose between people with and without blood cancer.</p> <br> <p><strong>Interpretation:</strong> Our study provides robust evidence which supports the use of COVID-19 vaccinations for people with blood cancer.</p> |
| spellingShingle | Copland, E Hirst, J Mi, E Patone, M Chen, D Coupland, C Hippisley-Cox, J Effectiveness and safety of COVID-19 vaccination in people with blood cancer |
| title | Effectiveness and safety of COVID-19 vaccination in people with blood cancer |
| title_full | Effectiveness and safety of COVID-19 vaccination in people with blood cancer |
| title_fullStr | Effectiveness and safety of COVID-19 vaccination in people with blood cancer |
| title_full_unstemmed | Effectiveness and safety of COVID-19 vaccination in people with blood cancer |
| title_short | Effectiveness and safety of COVID-19 vaccination in people with blood cancer |
| title_sort | effectiveness and safety of covid 19 vaccination in people with blood cancer |
| work_keys_str_mv | AT coplande effectivenessandsafetyofcovid19vaccinationinpeoplewithbloodcancer AT hirstj effectivenessandsafetyofcovid19vaccinationinpeoplewithbloodcancer AT mie effectivenessandsafetyofcovid19vaccinationinpeoplewithbloodcancer AT patonem effectivenessandsafetyofcovid19vaccinationinpeoplewithbloodcancer AT chend effectivenessandsafetyofcovid19vaccinationinpeoplewithbloodcancer AT couplandc effectivenessandsafetyofcovid19vaccinationinpeoplewithbloodcancer AT hippisleycoxj effectivenessandsafetyofcovid19vaccinationinpeoplewithbloodcancer |